Director-linked entities trim Immunome (IMNM) stake with 201,050-share sale

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Immunome Inc. reported insider sales by entities associated with director Isaac Barchas. On June 30 and July 2, 2026, ABHMC II LLC and Arsenal Bridge Venture II-B LLC completed open‑market sales totaling 201,050 shares of Immunome common stock under pre‑arranged Rule 10b5‑1 trading plans.

The filing shows weighted average sale prices of $21.12, $22.35, and $23.33 across the three reported transactions. After these sales, entities associated with Barchas held 208,504 shares indirectly, while Barchas’s direct holdings were reported at 103,259 shares. He disclaims beneficial ownership beyond any pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 201,050 shares ($4,393,024)

Net Sell 4 txns

Insider Barchas Isaac

Role null

Sold 201,050 shs ($4.39M)

Type	Security	Shares	Price	Value
Sale	Common Stock	75,665	$22.35	$1.69M
Sale	Common Stock	24,335	$23.33	$568K
Sale	Common Stock	101,050	$21.12	$2.13M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 232,839 shares (Indirect, See footnote); Common Stock — 103,259 shares (Direct, null)

Footnotes (1)

The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026. The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B. The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC ("ABV II") and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by ABV II to its members of the shares received in such distributions by members, including the Reporting Person. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13.

Key Figures

Total shares sold: 201,050 shares Weighted average price 6/30 sale: $21.12/share Weighted average price 7/2 sale (first): $22.35/share +4 more

7 metrics

Total shares sold 201,050 shares Aggregate open-market sales reported in this Form 4

Weighted average price 6/30 sale $21.12/share June 30, 2026 open-market sale

Weighted average price 7/2 sale (first) $22.35/share July 2, 2026 open-market sale

Weighted average price 7/2 sale (second) $23.33/share July 2, 2026 open-market sale

Indirect holdings after final sale 208,504 shares Total shares reported as indirectly held following July 2, 2026 transactions

Direct holdings reported 103,259 shares Direct common stock holdings as of June 30, 2026

Entity sale allocation 100,000 & 1,050 shares June 30, 2026 sale split between ABHMC II LLC and ABV II-B

Key Terms

Rule 10b5-1 trading plans, pro rata distributions in kind, pecuniary interest, beneficial ownership, +1 more

5 terms

Rule 10b5-1 trading plans regulatory

"The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC and ABV II-B."

Rule 10b5-1 trading plans are written, pre-arranged instructions that allow company insiders (such as executives or directors) to automatically buy or sell their company's stock at specified times or under set conditions, like a standing instruction or automated thermostat for trades. They matter to investors because these plans provide a legal defense against insider‑trading accusations and create predictable insider trading patterns that can help signal whether sales are routine portfolio management or potentially meaningful to the company’s outlook.

pro rata distributions in kind financial

"The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration."

pecuniary interest financial

"The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any."

beneficial ownership regulatory

"This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

weighted average sale price financial

"The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 08:32 PM Accepted by SEC EDGAR 07/02/2026 - 08:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barchas Isaac

(Last)

(First)

(Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL

WASHINGTON

98011

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/30/2026		S⁽¹⁾		101,050⁽²⁾	D	$21.12⁽³⁾	308,504	I	See footnotes⁽⁴⁾⁽⁵⁾
Common Stock	07/02/2026		S⁽¹⁾		75,665	D	$22.35⁽⁶⁾	232,839	I	See footnote⁽⁷⁾
Common Stock	07/02/2026		S⁽¹⁾		24,335	D	$23.33⁽⁸⁾	208,504	I	See footnote⁽⁷⁾
Common Stock								103,259⁽⁹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026.

2. The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B.

3. The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC ("ABV II") and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock.

5. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

6. The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

7. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

8. The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

9. The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by ABV II to its members of the shares received in such distributions by members, including the Reporting Person. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13.

	/s/ Sandra Stoneman, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Immunome (IMNM) report for Isaac Barchas?

Immunome reported that entities associated with director Isaac Barchas sold 201,050 shares of common stock. The sales occurred on June 30 and July 2, 2026, in open‑market transactions, and are detailed as three separate trades with disclosed weighted average prices and post‑transaction holdings.

Were the Immunome (IMNM) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the sales occurred automatically under Rule 10b5‑1 trading plans adopted by ABHMC II LLC and Arsenal Bridge Venture II‑B LLC on March 31, 2026. Such pre‑arranged plans schedule trades in advance, reducing the significance of trade timing for interpreting insider sentiment.

How many Immunome (IMNM) shares did entities linked to Isaac Barchas sell, and at what prices?

Entities linked to Isaac Barchas sold a total of 201,050 Immunome common shares. The filing reports weighted average sale prices of $21.12, $22.35, and $23.33 for the three open‑market transactions, with detailed price ranges available upon request from the company, SEC staff, or security holders.

What Immunome (IMNM) stake remains after the reported insider sales?

After the reported transactions, indirect holdings associated with Isaac Barchas totaled 208,504 shares of Immunome common stock. The filing also shows a separate direct holding of 103,259 shares. Together, these entries outline the remaining stake visible in this Form 4, combining both direct and indirect positions.

Were the Immunome (IMNM) shares sold directly by Isaac Barchas or by affiliated entities?

The sales were executed by ABHMC II LLC and Arsenal Bridge Venture II‑B LLC, entities with which Isaac Barchas is associated. He holds powers of attorney over their shares but disclaims beneficial ownership except for any pecuniary interest, so the transactions are attributed to those entities rather than personal accounts.

How were the June 30, 2026 Immunome (IMNM) insider sales allocated between entities?

The filing explains that, in the June 30, 2026 transaction, 100,000 shares were sold by ABHMC II LLC and 1,050 shares were sold by Arsenal Bridge Venture II‑B LLC. After this trade, ABHMC II LLC continued to own 308,504 shares of Immunome common stock, according to the referenced footnote disclosure.